Explore the latest news and publications, innovation milestones, and drug-device insights from PARI and our pharmaceutical partners leveraging eFlow® Technology.
LAMIRA®, an eFlow® Technology nebulizer, expected to launch in Japan as a medical device for exclusive administration of ARIKAYCE® (amikacin liposome inhalation suspension)
Santhera Announces Positive Results with Lonodelestat in Early Phase Cystic Fibrosis Trial
Insmed Initiates Frontline Clinical Trial Program for ARIKAYCE® (amikacin liposome inhalation suspension) in Patients with MAC Lung Disease
Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub.
Polyphor receives approval to start first in human clinical trial of inhaled antibiotic murepavadin
